Αρχική World News Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF... World News Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC Από Ogkologos - 23 Ιουλίου, 2026 228 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER Cohort 3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR After a Breast Cancer Diagnosis, Men May Be More Likely to... 2 Οκτωβρίου, 2019 Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... 5 Μαΐου, 2022 Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... 15 Ιουνίου, 2022 Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial 5 Δεκεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France Child Cancer Patient And His Dad Have A Little Fun When... Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... EMA Recommends Granting a Marketing Authorisation for Acalabrutinib
